511 related articles for article (PubMed ID: 30342879)
21. The efficacy of the Peginterferon treatment in chronic hepatitis HDV and compensate liver cirrhosis.
Tugui L; Dumitru M; Iacob S; Gheorghe L; Preda C; Dinu I; Becheanu G; Dumbrava M; Nicolae I; Andrei A; Lupu A; Diculescu M
Rev Med Chir Soc Med Nat Iasi; 2014; 118(2):368-75. PubMed ID: 25076702
[TBL] [Abstract][Full Text] [Related]
22. Association Between Level of Hepatitis D Virus RNA at Week 24 of Pegylated Interferon Therapy and Outcome.
Keskin O; Wedemeyer H; Tüzün A; Zachou K; Deda X; Dalekos GN; Heidrich B; Pehlivan S; Zeuzem S; Yalçın K; Gürel S; Tabak F; Idilman R; Bozkaya H; Manns M; Yurdaydin C
Clin Gastroenterol Hepatol; 2015 Dec; 13(13):2342-49.e1-2. PubMed ID: 26044319
[TBL] [Abstract][Full Text] [Related]
23. Hepatitis delta and HIV infection.
Calle Serrano B; Manns MP; Wedemeyer H
Semin Liver Dis; 2012 May; 32(2):120-9. PubMed ID: 22760651
[TBL] [Abstract][Full Text] [Related]
24. Long-term effects of interferon-based therapy for chronic hepatitis C.
Yu ML; Huang CF; Dai CY; Huang JF; Chuang WL
Oncology; 2007; 72 Suppl 1():16-23. PubMed ID: 18087178
[TBL] [Abstract][Full Text] [Related]
25. HDV evolution-will viral resistance be an issue in HDV infection?
Tabernero D; Cortese MF; Buti M; Rodriguez-Frias F
Curr Opin Virol; 2018 Oct; 32():100-107. PubMed ID: 30415162
[TBL] [Abstract][Full Text] [Related]
26. Does antiviral therapy reduce the risk of hepatocellular carcinoma in patients with chronic hepatitis C?
Michielsen P; Ho E; Francque S
Minerva Gastroenterol Dietol; 2012 Mar; 58(1):65-79. PubMed ID: 22419005
[TBL] [Abstract][Full Text] [Related]
27. [Hepatitis D: forgotten but not gone].
Moradpour D; Negro F
Rev Med Suisse; 2010 Sep; 6(261):1656-9. PubMed ID: 20939399
[TBL] [Abstract][Full Text] [Related]
28. Maintenance therapy with peginterferon alfa-2b does not prevent hepatocellular carcinoma in cirrhotic patients with chronic hepatitis C.
Bruix J; Poynard T; Colombo M; Schiff E; Burak K; Heathcote EJ; Berg T; Poo JL; Mello CB; Guenther R; Niederau C; Terg R; Bedossa P; Boparai N; Griffel LH; Burroughs M; Brass CA; Albrecht JK;
Gastroenterology; 2011 Jun; 140(7):1990-9. PubMed ID: 21419770
[TBL] [Abstract][Full Text] [Related]
29. Treatment of delta hepatitis.
Gunsar F
Expert Rev Anti Infect Ther; 2013 May; 11(5):489-98. PubMed ID: 23627855
[TBL] [Abstract][Full Text] [Related]
30. [Chronic hepatitis B and D (delta) : Current and future treatments].
Wortmann N; Höner Zu Siederdissen C; Cornberg M
Internist (Berl); 2018 Jun; 59(6):519-527. PubMed ID: 29761292
[TBL] [Abstract][Full Text] [Related]
31. Hepatitis delta virus: From biological and medical aspects to current and investigational therapeutic options.
Alfaiate D; Dény P; Durantel D
Antiviral Res; 2015 Oct; 122():112-29. PubMed ID: 26275800
[TBL] [Abstract][Full Text] [Related]
32. Treatment of hepatitis delta virus genotype 3 infection with peg-interferon and entecavir.
Borzacov LM; de Figueiredo Nicolete LD; Souza LF; Dos Santos AO; Vieira DS; Salcedo JM
Int J Infect Dis; 2016 May; 46():82-8. PubMed ID: 27005283
[TBL] [Abstract][Full Text] [Related]
33. Hepatitis delta virus and hepatocellular carcinoma: an update.
Romeo R; Petruzziello A; Pecheur EI; Facchetti F; Perbellini R; Galmozzi E; Khan NU; Di Capua L; Sabatino R; Botti G; Loquercio G
Epidemiol Infect; 2018 Oct; 146(13):1612-1618. PubMed ID: 29991359
[TBL] [Abstract][Full Text] [Related]
34. Hepatitis D Virus Infection of Mice Expressing Human Sodium Taurocholate Co-transporting Polypeptide.
He W; Ren B; Mao F; Jing Z; Li Y; Liu Y; Peng B; Yan H; Qi Y; Sun Y; Guo JT; Sui J; Wang F; Li W
PLoS Pathog; 2015 Apr; 11(4):e1004840. PubMed ID: 25902143
[TBL] [Abstract][Full Text] [Related]
35. Anti-HDV immunoglobulin M testing in hepatitis delta revisited: correlations with disease activity and response to pegylated interferon-α2a treatment.
Mederacke I; Yurdaydin C; Dalekos GN; Bremer B; Erhardt A; Cakaloglu Y; Yalcin K; Gurel S; Zeuzem S; Zachou K; Bozkaya H; Dienes HP; Manns MP; Wedemeyer H;
Antivir Ther; 2012; 17(2):305-12. PubMed ID: 22293066
[TBL] [Abstract][Full Text] [Related]
36. HBV/HDV Coinfection: A Challenge for Therapeutics.
Koh C; Da BL; Glenn JS
Clin Liver Dis; 2019 Aug; 23(3):557-572. PubMed ID: 31266627
[TBL] [Abstract][Full Text] [Related]
37. Efficacy of peginterferon alpha-2b in chronic hepatitis delta: relevance of quantitative RT-PCR for follow-up.
Castelnau C; Le Gal F; Ripault MP; Gordien E; Martinot-Peignoux M; Boyer N; Pham BN; Maylin S; Bedossa P; Dény P; Marcellin P; Gault E
Hepatology; 2006 Sep; 44(3):728-35. PubMed ID: 16941695
[TBL] [Abstract][Full Text] [Related]
38. Epidemiology and patient characteristics of hepatitis D virus infection in the West of Scotland 2011-2016.
Jackson C; Gunson RN; Bradley-Stewart A; Bennett S; Black H; Kennedy N; Bell DJ
J Viral Hepat; 2018 Nov; 25(11):1395-1396. PubMed ID: 29851188
[No Abstract] [Full Text] [Related]
39. Current management of delta hepatitis.
Rizzetto M
Liver Int; 2013 Feb; 33 Suppl 1():195-7. PubMed ID: 23286865
[TBL] [Abstract][Full Text] [Related]
40. A population-based study of hepatitis D virus as potential risk factor for hepatocellular carcinoma.
Ji J; Sundquist K; Sundquist J
J Natl Cancer Inst; 2012 May; 104(10):790-2. PubMed ID: 22423008
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
